Li Yaosheng, Wu Honghui, Jiang Xinchi, Dong Yunfei, Zheng Juanjuan, Gao Jianqing
Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, Zhejiang University, Hangzhou 310058, China.
Acta Pharm Sin B. 2022 Aug;12(8):3215-3232. doi: 10.1016/j.apsb.2022.04.001. Epub 2022 Apr 7.
The clinical translation of stem cells and their extracellular vesicles (EVs)-based therapy for central nervous system (CNS) diseases is booming. Nevertheless, the insufficient CNS delivery and retention together with the invasiveness of current administration routes prevent stem cells or EVs from fully exerting their clinical therapeutic potential. Intranasal (IN) delivery is a possible strategy to solve problems as IN route could circumvent the brain‒blood barrier non-invasively and fit repeated dosage regimens. Herein, we gave an overview of studies and clinical trials involved with IN route and discussed the possibility of employing IN delivery to solve problems in stem cells or EVs-based therapy. We reviewed relevant researches that combining stem cells or EVs-based therapy with IN administration and analyzed benefits brought by IN route. Finally, we proposed possible suggestions to facilitate the development of IN delivery of stem cells or EVs.
基于干细胞及其细胞外囊泡（EVs）的疗法在中枢神经系统（CNS）疾病的临床转化方面正蓬勃发展。然而，目前给药途径的中枢神经系统递送不足和滞留以及侵入性，阻碍了干细胞或细胞外囊泡充分发挥其临床治疗潜力。鼻内（IN）给药是解决这些问题的一种可能策略，因为鼻内途径可以非侵入性地绕过血脑屏障，并适合重复给药方案。在此，我们概述了与鼻内途径相关的研究和临床试验，并讨论了采用鼻内给药来解决基于干细胞或细胞外囊泡疗法中问题的可能性。我们回顾了将基于干细胞或细胞外囊泡的疗法与鼻内给药相结合的相关研究，并分析了鼻内途径带来的益处。最后，我们提出了可能的建议，以促进干细胞或细胞外囊泡鼻内给药的发展。
